Company intelligence / Profile preview

Theranexus

Ownership: Private
Employees: ~12
Development stage: Other

Overview

Theranexus has a proprietary platform generating drug candidates that modulate both neuronal and glial cell activity. Its lead candidate for Batten disease is in clinical development. The company’s approach aims to improve efficacy of existing psychotropic drugs by combining them with glial cell modulators. Three programs are ongoing in clinical development as of 2024; no pivotal or late-stage results have been publicly reported yet.

Therapeutic areas: Neurology
Modalities: Small molecules (drug combinations targeting neurons and glial cells/astrocytes)
Industry: Biotech

Drug pipeline

5 assets

BBDF-101

4 more assets in the full pipeline.

Partnerships

Exeltis (Insud Pharma) – licensing agreement to commercialize Tx01 for two rare neurological disorders announced in 2024

Beyond the preview

Go deeper on Theranexus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theranexus.